BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
June 07, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.
BioCardia Announces Reverse Stock Split
May 21, 2024 17:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
May 14, 2024 16:02 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
May 09, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
May 01, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
April 25, 2024 09:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
March 27, 2024 16:00 ET
|
BioCardia, Inc.
BioCardia®, Inc. today reported financial results for the year ended December 31, 2023
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
March 20, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
March 13, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
March 12, 2024 07:00 ET
|
BioCardia, Inc.
Centers for Medicare & Medicaid Services (CMS) approves reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP heart failure study